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An HK2 Antisense Oligonucleotide Induces
Synthetic Lethality inHK1HK2þMultipleMyeloma
Shili Xu1, Tianyuan Zhou2, Hanna M. Doh1, K Ryan Trinh3, Art Catapang1,
Jason T. Lee1,4,5, Daniel Braas1,6, Nicholas A. Bayley1, Reiko E. Yamada7,
Alex Vasuthasawat3, Joshua P. Sasine5,7, JohnM.Timmerman5,7, SarahM. Larson5,7,
Youngsoo Kim2, A. Robert MacLeod2, Sherie L. Morrison3,5, and
Harvey R. Herschman1,4,5,8,9
Abstract
A synthetically lethal precision medicine therapy for HK1-HK2+ multiple myeloma using
an HK2 antisense oligonucleotide, metformin, and perhexiline.
Most normal
tissues
ToleratedTolerated
HK1+HK2+
multiple
myeloma
HK2-ASO Met
formin Perhexi
line
HK1–HK2+
multiple
myeloma
Glucose-6-P Glucose-6-P
GlucoseGlucose
HK1 HK2 HK2
Synthetically lethal
Although the majority of adult tissues express
only hexokinase 1 (HK1) for glycolysis, most can-
cers express hexokinase 2 (HK2) and many coex-
press HK1 and HK2. In contrast to HK1þHK2þ
cancers, HK1HK2þ cancer subsets are sensitive to
cytostasis inducedbyHK2shRNAknockdownandare
also sensitive to synthetic lethality in response to the
combination of HK2shRNA knockdown, an oxida-
tive phosphorylation (OXPHOS) inhibitor diphe-
nyleneiodonium (DPI), and a fatty acid oxidation
(FAO) inhibitor perhexiline (PER). The majority
of human multiple myeloma cell lines are
HK1HK2þ. Here we describe an antisense oligo-
nucleotide (ASO) directed against human HK2
(HK2-ASO1), which suppressed HK2 expression in
humanmultiple myeloma cell cultures and human
multiple myeloma mouse xenograft models. The
HK2-ASO1/DPI/PER triple-combination achieved
synthetic lethality in multiple myeloma cells in
culture and prevented HK1HK2þ multiple mye-
loma tumorxenograft progression.DPIwas replace-
able by the FDA-approvedOXPHOS inhibitor met-
formin (MET), both for synthetic lethality in culture and for inhibition of tumor xenograft progression. In addition, we used an
ASO targetingmurineHK2 (mHK2-ASO1) to validate the safety ofmHK2-ASO1/MET/PER combination therapy inmice bearing
murinemultiplemyeloma tumors.HK2-ASO1 is theﬁrst agent that shows selectiveHK2 inhibition and therapeutic efﬁcacy in cell
culture and in animal models, supporting clinical development of this synthetically lethal combination as a therapy for
HK1HK2þ multiple myeloma.
Signiﬁcance:Aﬁrst-in-classHK2antisense oligonucleotide suppressesHK2expression in cell culture and in in vivo, presenting
an effective, tolerated combination therapy for preventing progression of HK1HK2þ multiple myeloma tumors.
Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/79/10/2748/F1.large.jpg.
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Introduction
Multiplemyeloma, a clonal proliferation disorder ofmalignant
plasma cells, is the second most common hematologic malig-
nancy. Despite application of currently available therapies (e.g.,
proteasome inhibitors, immunomodulatory drugs, tumor cell-
targetingmonoclonal antibodies, autologous stem cell transplan-
tation), multiple myeloma is still regarded as incurable (1);
moreover, nearly all patients exhaust available therapeutic
options, including clinical trials. The projected 60% increase in
new multiple myeloma cases between 2010 and 2030 highlights
an urgent need for effective therapies (2).
Nearly all cancers exhibit increased glycolysis—originally
described almost 90 years ago as the "Warburg effect" (3).
Although suggested to provide adequate energy (ATP), reducing
equivalents, and/or precursors for synthesizing building blocks
for cancer cell survival and proliferation, the reason(s) for
increased glycolysis in cancer cells is/are still ambiguous and
controversial (4).
Despite many attempts to inhibit the increased glycolysis
observed in cancers, no clinical therapy based on this approach
has been successful, partially because of the conserved glycolytic
pathways present in normal and cancer cells, and existence of
alternative metabolic pathways in cancers (5). The ﬁrst enzymatic
step in glycolysis, conversion of glucose to glucose-6-phosphate,
is catalyzed by members of the hexokinase (HK) family (6).
Most tissues express only HK1; liver expresses only HK4 (also
known as glucokinase). However, although HK2 is expressed in
only a few normal tissues (e.g., heart, muscle, adipose tissue)
and is expendable when globally deleted in adult mice (7),
most tumors, regardless of tissue of origin, express HK2 in
addition to HK1 (7–11).
In a search for cancers that depend primarily on HK2 expres-
sion, we observed that cancers from nearly all tissues have subsets
ofHK1HK2þ tumors (11).HK2shRNA expressionhadno effect on
cell proliferation or xenograft tumor progression for HK1þHK2þ
tumors of differing origin; in contrast, HK2shRNA expression
suppressed cultured cell proliferation and xenograft tumor pro-
gression of these HK1HK2þ tumors (11).
Using both HK1HK2þ and HK1þHK2þ liver cancer cell lines
as well as HK1HK2þ isogenic cancer cell lines derived from
parental HK1þHK2þ cancer cells by CRISPR Cas9 deletion, a high
throughput screen identiﬁed diphenyleneiodonium (DPI), a
mitochondrial complex I inhibitor, as a synergistic partner in
inhibiting HK1HK2þ tumor progression (12). Fatty acid oxida-
tion (FAO) inhibition by the clinical drug perhexiline (PER)
reduces ATP synthesis, and results in effective blockade of
HK1HK2þ tumor progression by the HK2shRNA/DPI/PER com-
bination. In contrast, HK1þHK2þ tumor progression was unaf-
fected by this combination treatment (12).
Although HK2shRNA used in our previous studies lacks trans-
lational potential, it served as a valuable research tool to establish
a proof-of-concept precision therapeutic strategy, using the
HK2shRNA/DPI/PER combination, for HK1HK2þ liver cancer
cells. However, the therapeutic challenges for this potential ther-
apy include extending its efﬁcacy to HK1HK2þ cancer subsets
from other tissues of origin, identifying a therapeutically tractable
method to preferentially inhibit HK2, and ﬁnding appropriate
clinical alternatives to inhibit ATP generation by OXPHOS.
In examining the Cancer Cell Line Encyclopedia (CCLE) data-
set,we found thatmultiplemyelomahas the highest percentage of
HK1HK2þ tumor subset members. Our objectives in this study
were four fold: (i) to extendour combination of inhibition ofHK2
expression/activity, OXPHOS, and FAO to HK1HK2þ multiple
myeloma cancers; (ii) to identify a potential clinically applicable
therapeutic agent, as opposed to the research tool HK2shRNA, to
speciﬁcally suppress HK2 expression/activity; (iii) to identify a
more suitable clinical therapeutic alternative to inhibit OXPHOS;
and (iv) to determine the tolerability of the combination by
normal tissues in living animals. Here we used an HK2 antisense
oligonucleotide (ASO), HK2-ASO1, to suppress human HK2
expression. Using human HK1HK2þ multiple myeloma cell
lines as a model, we demonstrate that the HK2-ASO1/DPI/PER
combination potently suppresses tumor progression. We also
demonstrate thatmetformin (MET), an FDA-approvedmitochon-
drial complex I inhibitor, can replace DPI in the synthetically
lethal combination, improving the translational potential of the
combination therapy. Finally, we used a mouse HK2 ASO to
demonstrate, in HK1HK2þ mouse multiple myeloma tumor
bearing mice, the efﬁcacy and safety of the HK2-ASO/MET/PER
combination therapy.
Materials and Methods
Cell lines
Human multiple myeloma cell lines OPM1, OPM2,
RPMI8226, and XG1 from the ATCC were cultured in Advanced
RPMI1640þ10%FBS.Humanmultiplemyeloma cell linesH929,
U266, MM144, and S6B45 from ATCC were cultured in
RPMI1640þ10% FBS. Mouse multiple myeloma P3  63Ag
(P3) cells were cultured in IMDMþ10% FBS. Cells were main-
tained at 37C in 5% CO2/95% air. Cell lines were used between
passages 1 and 20, and were routinely authenticated based on
morphology, growth characteristics, and HK expression proﬁles
according to CCLE gene expression dataset. Mycoplasma con-
tamination was routinely examined using MycoAlert (Lonza,
#LT07-318).
ASOs
Gen 2.5 ASOs with constrained ethyl (cEt) chemistry were
synthesized and used as described previously (13, 14). Scrambled
ASOs were included in each study as a negative control. In cell
culture, ASOs were delivered to the cells via free uptake, without
using any transfecting agents. In animal studies, ASOs were
dissolved in PBS and injected subcutaneously.
Cell proliferation assay
Cell proliferation in 96-well plates was measured by CellTiter
96 AQueous One Solution Assay (MTS; Promega, #G5430) fol-
lowing the manufacturer's instructions.
Annexin V apoptosis assay
Cells were pretreated with ASOs for 3 days before the addition
of DPI, MET, or PER. Three days later, cells were harvested,
washed, and stained using the Vybrant Apoptosis Kit (Thermo-
Fisher Scientiﬁc) according to the manufacturer's protocol.
Stained samples were then examined on a Becton Dickenson
FACSVerse ﬂow cytometer and analyzed using FlowJo software.
Assessment of xenograft multiple myeloma progression
In subcutaneous models, 3  106 cells suspended in 100 mL
RPMI/Matrigel (1:1) were implanted subcutaneously in NSG
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mice under aseptic conditions. Multiple myeloma progression
was assessed by biweekly measurement of tumor diameters with
a Vernier caliper. Tumor volume (mm3) was calculated as ¼ D 
d2/2, whereD and d are the longest and shortest tumor diameters.
Treatments started when tumors reached 200 mm3. In dissemi-
natedmultiplemyelomamodels, 1106P3/HK1--mCherry-LUC
cells or 3  106 RPMI8226-LUC cells suspended in 100 mL PBS
were injected intravenously. Multiple myeloma progression was
monitored once weekly by bioluminescence imaging (BLI). Treat-
ments started when tumors were detected by BLI. To test our
treatments, mice were randomized into indicated treatment
groups to receive daily treatment for 5 days per week, with 2-day
breaks between weeks. ASOs were given by subcutaneous injec-
tion at 50 mg/kg. DPI and PER were dissolved in DMSO as stock
solutions at 30 and 300 mg/mL, respectively, and then diluted in
5% (w/v) hydroxyl-propyl-beta-cyclodextrin (Sigma). MET was
dissolved in 5% (w/v) hydroxyl-propyl-beta-cyclodextrin. All
solutions for injection were ﬁltered. DPI, PER, and MET were
given at 2, 30, and 250 mg/kg through intraperitoneal injec-
tion. All reported animal studies were approved by the UCLA
Chancellor's Animal Research Committee (ARC) under proto-
col number 2015-067-11.
In vivo assessment of tumor glucose consumption by 18F-FDG
PET/CT
Animals without fasting were warmed on a heating pad for 30
minutes and then injected via the tail veinwith 2.8MBqof clinical-
grade 18F-ﬂuorodeoxyglucose (18F-FDG). Animals underwent a 1
hour conscious 18F-FDG biodistribution period on a heating pad
prior to imaging. PET and CT scans were conducted on a G8
combinedPET/CT instrument (SoﬁeBiosciences, Inc.)with a600-s
PET acquisition and maximum-likelihood expectation maximiza-
tion reconstruction, and with a 50-s CT acquisition and Feldkamp
reconstruction. PET data were converted to percent-injected dose
per gram (%ID/g) and PET/CT images were co-registered. Mean
values of PET signal intensity from tumor region-of-interest (ROI)
were analyzed using AMIDE software v1.0.4.
Statistical analysis
The Student t test was used for statistical analysis. P values were
determined using Prism 7 (GraphPad Software, Inc.). Differences
were considered statistically signiﬁcant at P < 0.05.
Results
A substantial subset of multiple myeloma cell lines does not
express HK1
Analysis of HK1 and HK2 mRNA expression in the CCLE
database revealed that 54% of the human multiple myeloma cell
lines in this collection are HK1HK2þ (Fig. 1A and B). Among all
human cancer types in the CCLE, multiple myeloma has the
largest percentage of HK1HK2þ cell lines (54%; 14/26), fol-
lowed by liver cancer (38%; 9/24) and colorectal cancer (10%;
6/58; Fig. 1B). Existence of the HK1HK2þ characteristic in many
multiple myeloma cell lines was conﬁrmed at the protein level
(Fig. 1C).
To consider HK1 and HK2 expression in multiple myeloma
clinical samples, we analyzed HK1 and HK2 mRNA expression
proﬁles in themultiplemyelomapatient samples from theRelating
ClinicalOutcomes inmultiplemyeloma to Personal Assessment of
Genetic Proﬁle (CoMMpass) data base (https://research.themmrf.
org; refs. 15, 16), and compared them to those of the multiple
myeloma cell lines in the CCLE data base. Although the absolute
levelsofHK1andHK2mRNAsbetween theCCLEdatabaseand the
CoMMpass data base cannot be directly compared, due to differ-
ences in sequencing methods and approaches, the relative levels of
expression can be compared. We deﬁned the frequency of "low"
expression of HK1 in multiple myeloma cell lines (data from the
CCLE data set), and identiﬁed the equivalent proportion of the
multiple myelomas in the patient population (data from the
CoMMpass data base; Fig. 1D). We then compared HK2 mRNA
levels in the "HK1 low" subpopulations from the two data bases.
HK2 expression in the "HK1 low" and "HK1 high" subpopulations
are the same inmultiplemyeloma CCLE andCoMMpass data base
members (Fig. 1D), indicating a similar high frequency of the
HK1HK2þ phenotype in clinical multiple myeloma patient
samples.
Differential gene expression analysis of all multiple myeloma
cell lines in the CCLE dataset reveals distinct gene expression
patterns between the HK1HK2þ and the HK1þHK2þ multiple
myeloma cell lines, further supporting classiﬁcation of the
HK1HK2þ multiple myelomas and the HK1þHK2þ multiple
myelomas as distinct subtypes (Fig. 1E). Pathway enrichment
analysis suggests that these differentially expressed genes are
involved in pathways that include endocytosis, N-glycan biosyn-
thesis, glycosphingolipid biosynthesis, galactose metabolism,
homologous recombination, regulation of actin cytoskeleton,
fructose and mannose metabolism, and amino sugar and nucle-
otide sugar metabolism (Fig. 1F). These data may suggest addi-
tional potential biomarkers and/or therapeutic targets for the
HK1HK2þ and HK1þHK2þ multiple myeloma subtypes.
Development of an HK2 ASO to suppress HK2 expression and
HK1HK2þ multiple myeloma cell proliferation
Extensive efforts have been made to develop HK2-speciﬁc
small-molecule inhibitors (17), but no speciﬁc HK2 inhibitor
has been reported to exhibit in vivo systemic efﬁcacy. To translate
our previous ﬁndings, using genetic approaches, that HK2 is
targetable to slow the progression of HK1HK2þ subsets of
cancer, we used our latest Generation 2.5 Chemistry technology
to make HK2 ASOs as pharmacologic HK2-targeting agents to
treat HK1HK2þ multiple myelomas. We identiﬁed two active
HK2ASOs (HK2-ASO1 andHK2-ASO2; Supplementary Fig. S1A)
after in vitro screening and tolerability study in mice. In cell
culture, delivered via free uptake without using any transfecting
agents, HK2-ASO1 was more effective than HK2-ASO2 in sup-
pressingHK2 expression, in a dose-dependentmanner, in a broad
panel of multiple myeloma cell lines of both the HK1HK2þ and
the HK1þHK2þ subtypes, without altering HK1 protein levels
(Fig. 2A).
Glucose consumption and lactate production are metabolic
markers of HK enzymatic activity in driving glycolysis. Treatment
with HK2-ASO1 reduced both glucose consumption and lactate
production (Fig. 2B). However, although HK2-ASO1 and HK2-
ASO2 suppressed HK2 expression in both HK1HK2þ and
HK1þHK2þmultiplemyeloma cell lines, bothASOs only reduced
proliferation of multiple myeloma cells with the HK1HK2þ
characteristic (Fig. 2C); they had no signiﬁcant effect on
HK1þHK2þ multiple myeloma cell proliferation (Fig. 2C),
despite comparable HK2 knockdown in all cell lines. Cell-cycle
analyses showed that HK2-ASO1, compared with a control
ASO (ASO-Ctrl), signiﬁcantly decreased S-phase proliferating cell
Xu et al.
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population in HK1HK2þ multiple myeloma cells, but not in
HK1þHK2þmultiplemyeloma cells (Supplementary Fig. S1B). In
addition, HK2-ASO1 had only minor effect on increasing multi-
ple myeloma cell death, as indicated by the <10% sub-G1 cell
population (Supplementary Fig. S1C).
The selective growth inhibitory effect of HK2-ASO1 in
HK1HK2þ multiple myeloma cells in cell culture was validated
both by cell counting (Supplementary Fig. S1D) and by colony
formation assays (Supplementary Fig. S1E), compared with ASO-
Ctrl. These observations with ASO HK2-selective inhibitors are
consistent with our previous ﬁndings with other cancer cells using
HK2shRNA (11, 12), demonstrating that the cytostatic effect ofHK2
knockdown or knockout is limited to the HK1HK2þ cancer
subsets.
Figure 1.
A subset of humanmultiple myeloma cell lines are HK1HK2þ. A, HK1HK2þmultiple myeloma cell lines are present in the CCLE collection (http://oasis-
genomics.org). HK1 and HK2mRNA expression of 935 cancer cell lines, including 26multiple myeloma cell lines, are shown. Each data point represents a cell line.
The box indicates "HK1HK2þ" cell lines, deﬁned as HK2 > 1 TPM and HK1 < 10 TPM. TPM, transcripts per million. B,Multiple myeloma has the largest percentage of
HK1HK2þ cell lines among all CCLE cancers from different tissues of origin. C, Validation of HK1 and HK2 protein levels in representative humanmultiple
myeloma cell lines. D, A comparison of HK1 and HK2 expression proﬁles betweenmultiple myeloma cell lines (CCLE) and multiple myeloma patient samples (the
CoMMpass RNA-Seq datasets). E, Differential gene expression proﬁles of HK1HK2þ and HK1þHK2þmultiple myeloma cell lines. All multiple myeloma cell lines in
the CCLE dataset were analyzed for differential gene expression across 18,920 genes. Sixty-three genes with signiﬁcant differences (adjusted P < 0.05) between
the two populations are shown. F, Pathway enrichment analysis of differentially expressed genes in E (http://amp.pharm.mssm.edu/Enrichr/).
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The combination of HK2-ASO1, partial inhibition of OXPHOS,
and FAO is synthetically lethal for HK1HK2þ multiple
myelomas
Wepreviously identiﬁed a small-moleculemitochondrial com-
plex I inhibitor, DPI, from a high throughput screen as a synthet-
ically lethal partner with HK2 shRNAs in HK1HK2þ liver cancer
cells (12). At concentrations (<100 nmol/L) we used in our
subsequent cell culture experiments DPI partially, but not
completely, inhibited mitochondrial OXPHOS (Supplementary
Fig. S2A). The synthetic lethality of the HK2shRNA þ DPI combi-
nation could be enhanced by the addition of the FAO inhibitor
PER (12). Consistent with our previous observations with HK2
shRNAs, the combination of HK2-ASO1 and DPI induced syn-
thetic lethality in HK1HK2þ multiple myeloma cell lines, but
had no discernable effect on viability or proliferation of
HK1þHK2þ U266 multiple myeloma cells (Fig. 3A; Supplemen-
tary Fig. S2B). Apoptosis induction by the HK2-ASO1/DPI com-
bination was also observed only in HK1HK2þ multiple myelo-
ma cell lines, but not in HK1þHK2þ multiple myeloma cells
(Fig. 3B). To test the sensitizing effect of PER (12), we lowered
HK2-ASO1 and DPI concentrations so that the HK2-ASO1/DPI
combination did not induce substantial apoptosis in HK1þHK2þ
OPM2 multiple myeloma cells (Fig. 3C). Addition of PER sensi-
tized these HK1HK2þ multiple myeloma cells to this HK2-
ASO1/DPI combination (Fig. 3C; Supplementary Fig. S2C). Tar-
geting the major bioenergy generation pathways in HK1HK2þ
multiple myeloma cell lines (HK2-driven glycolysis and
OXPHOS) with HK2-ASO1 and DPI triggered expression of an
apoptosis marker, cleaved PARP. Addition of PER to the HK2-
ASO1þ DPI combination further increased PARP cleavage
(Fig. 3D).
We also examined the effect of this triple combination on
human peripheral blood mononuclear cells (PBMC). Compared
with HK1þHK2þmultiple myeloma OCI-My5 cells, PBMCs have
highHK1 expression and lowHK2 expression (Fig. 3E). Although
HK2-ASO1 reduced HK2 levels in PBMCs (Fig. 3E), the combi-
nation of HK2-ASO1/DPI/PER had no signiﬁcant toxicity in
PBMCs (Fig. 3F), suggesting its potential safety for in vivo utility.
To further evaluate the speciﬁcity of our combination therapy
for HK1HK2þ multiple myeloma cells, we created an
HK1þHK2þ isogenic cell line (RPMI8226/HK1þHK2þ) from the
parental HK1HK2þ RPMI8226 cell line (Fig. 3G). Stable
Figure 2.
Development of human HK2 targeting ASOs. A, HK2-ASO1 and HK2-ASO2 suppress HK2 expression in a panel of HK1HK2þ and HK1þHK2þmultiple myeloma
cell lines. Cells were treated with HK2-ASO1 or HK2-ASO2 at indicated concentrations for 3 or 7 days. Cell lysates were examined for HK1 and HK2 protein levels.
B, HK2-ASO1 inhibits glucose consumption (top) and lactate production (bottom) more effectively in HK1HK2þmultiple myeloma cells than in HK1þHK2þ
multiple myeloma cells. Triplicate wells of cells were exposed to HK2-ASO1 for 7 days. Media were then refreshed and, after 24 hours, glucose (Gluc)
consumption and lactate (Lact) production were measured. C, HK2-ASO1 and HK2-ASO2 inhibit proliferation of HK1HK2þmultiple myeloma cells but not
HK1þHK2þmultiple myeloma cells. Cells were treated with HK2-ASO1 or HK2-ASO2 at indicated concentrations for 7 days. Cell proliferation was measured on
day 7 by MTS assays.  , P < 0.05; , P < 0.01;  , P < 0.001;  , P < 0.0001.
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expression of HK1 resulted in acquired resistance of RPMI8226
(HK1HK2þ) cells to the cytotoxicity of the HK2-ASO1/DPI/PER
combination in this isogenic cell line experiment (Fig. 3H), con-
ﬁrming the speciﬁcity of the synthetic lethality in HK1HK2þ
multiple myeloma cells.
HK2-ASO1 reducesHK2 expression and 18F-FDG accumulation
in xenograft multiple myeloma tumors in vivo
We next examined the ability of HK2-ASO1 to suppress HK2
expression in human multiple myeloma tumors in mouse xeno-
grafts. Subcutaneous injection of HK2-ASO1 effectively reduced
HK2 protein levels in both xenograft HK1HK2þOPM2 tumors
andHK1þHK2þU266 tumors, without affectingHK1 expression
(Fig. 4A). To demonstrate the biochemical consequences of
HK2-ASO1-suppressed HK2 expression in human HK1HK2þ
multiple myeloma tumors in vivo, we examined 18F-FDG accu-
mulation in HK1HK2þ OPM2 multiple myeloma xenograft
tumors, by 18F-FDG microPET analysis, in the presence of HK2-
ASO1 or ASO-Ctrl. Decrease in HK2 protein levels by HK2-ASO1
(Fig. 4A) signiﬁcantly reduced OPM2 tumor 18F-FDG accumu-
lation, as determined non-invasively by 18F-FDG PET imaging
(Fig. 4B and C).
HK2-ASO1 synergizes with DPI and PER to suppress
HK1HK2þ xenograft human multiple myeloma tumor
progression
We previously demonstrated the efﬁcacy of HK2shRNA-mediat-
ed suppression of HK2 expression in a therapeutic combination
with DPI and PER for HK1HK2þ liver cancer tumor progres-
sion (12). Here we tested HK2-ASO1 efﬁcacy, alone and in
combination with DPI and PER, on HK1HK2þ multiple mye-
loma xenograft tumor progression. HK2-ASO1 treatment was
started when subcutaneous OPM2 HK1HK2þ multiple myelo-
ma tumors reached 200 mm3 (day 1); DPI and PER treatments
were initiated on day 4. As a single agent, HK2-ASO1 did not
reduce OPM2 tumor progression to a statistically signiﬁcant level
(Fig. 4D). However, theHK2-ASO1/DPI combination signiﬁcant-
ly suppressed tumor progression, and addition of PER resulted in
a further reduction in tumor volume (Fig. 4D). HK2-ASO1, both
alone and in combination with DPI/PER, is tolerated by the
animals; no signiﬁcant change in body weight was detected
among the experimental groups (Supplementary Fig. S3A). How-
ever, it is important to note that HK2-ASO1 is speciﬁc for human
HK2 and does not match the mouse HK2 sequence. Therefore,
tolerability of human HK2-targeting HK2-ASO1 in xenograft
Figure 3.
The HK2-ASO1/DPI/PER combination causes synthetic lethality in HK1HK2þmultiple myeloma cells. A, The combination of HK2-ASO1 and DPI causes selective
synthetic lethality in HK1HK2þmultiple myeloma cells. Cells were pretreated with ASOs (10 mmol/L) for 3 days, followed by the addition of DPI (50 nmol/L) for
another 3 days. Cell viability was determined by trypan blue staining. B, The combination of HK2-ASO1 and DPI causes selective apoptosis in HK1HK2þmultiple
myeloma cells. Cells were pretreated with ASOs (10 mmol/L) for 3 days, followed by the addition of DPI (50 nmol/L for OPM2 and 25 nmol/L for S6B45 and U266)
for another 3 days. Apoptosis (APO) was determined by quantiﬁcation of all Annexin V-positive events. C, PER sensitized HK1HK2þOPM2 cells to apoptosis
induced by the HK2-ASO1/DPI combination. Cells were pretreated with ASOs (5 mmol/L) for 3 days, followed by the addition of DPI (15 nmol/L) and PER
(5 mmol/L) for another 3 days. Apoptosis (APO) was determined by quantiﬁcation of all Annexin V-positive events. D, Effects of HK2-ASO1, DPI, and PER, alone
and in combination, on PARP cleavage in HK1HK2þOPM2 cells. E, Expression of HK1 and HK2 in PBMCs following treatment with 10 mmol/L ASO-Ctrl or
HK2-ASO1 for 3 days. F, HK2-ASO1/DPI/PER combination treatment has no signiﬁcant toxicity in PBMCs. PBMCswere pretreated with 10 mmol/L ASO-Ctrl or
HK2-ASO1 for 72 hours, followed by the exposure to ASO-Ctrl (10 mmol/L) or the combination HK2-ASO1 (10 mmol/L)/DPI (25 nmol/L)/PER (5 mmol/L) for an
additional period of 72 hours. Cell viability was determined by trypan blue staining in Countess II Cell Counter (Invitrogen). G, Stable expression of HK1 in
RPMI8226 cells. H, Effects of indicated treatments on cell proliferation of parental RPMI8226 (HK1HK2þ) and RPMI8226 (HK1þHK2þ). Cells were exposed to
ASOs (10 mmol/L) for 72 hours prior to the exposure to DPI (25 nmol/L) and/or PER (5 mmol/L) for another 72 hours. NS, not signiﬁcant.
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experiments does not indicate tolerability of HK2 silencing in the
triple combination in normallyHK2 expressing tissues (e.g., heart
and skeletal muscle).
At the end of the experiment, tumors were collected (Supple-
mentary Fig. S3B) and weighed (Supplementary Fig. S3C). Sig-
niﬁcant reductions in both tumor volume andweight occurred. In
contrast, DPI and PER, as single agents or in combination, did not
signiﬁcantly affect OPM2 tumor progression (Supplementary Fig.
S3D and S3E). In both the HK2-ASO1/DPI group and the HK2-
ASO1/DPI/PER group, increase in PARP cleavage was detected in
tumor homogenates of OPM2 HK1HK2þ multiple myeloma
tumors (Fig. 4E).
Unlike the HK1HK2þOPM2 tumors, HK1þHK2þU266mul-
tiple myeloma tumors were resistant to treatments with HK2-
ASO1, HK2-ASO1/DPI, and HK2-ASO1/DPI/PER (Fig. 4F). No
signiﬁcant difference was observed in tumor volume (Supple-
mentary Fig. S3F) or tumor weight (Supplementary Fig. S3G),
althoughHK2protein levels were substantially reduced in tumors
(Supplementary Fig. S3H). These in vivo data conﬁrm that HK2-
ASO1/DPI/PER combination therapy is effective in suppressing
HK1HK2þmultiple myeloma tumor xenograft progression, but
has no signiﬁcant effect onHK1þHK2þmultiple myeloma tumor
xenograft progression.
DPI can be replaced by MET in this combination therapy
Our data suggest that ASOs that suppress HK2 expression are a
potential clinical therapeutic approach to treating HK1HK2þ
multiple myeloma. Although DPI is a potent OXPHOS inhibitor
and has been demonstrated to synergize therapeutically with
HK2shRNA (12) and HK2-ASO1, DPI has not been tested in
humans. To move this combination therapy towards clinical
development, we tested the replacement of DPI with the FDA
approvedOXPHOS inhibitorMET. Like DPI, MET partially inhib-
ited mitochondrial respiration (Supplementary Fig. S4A), and
demonstrated synthetic lethality with HK2-ASO1 in cultured
HK1HK2þmultiple myeloma cells, but had no signiﬁcant effect
on HK1þHK2þ U266 multiple myeloma cells (Fig. 5A; Supple-
mentary Fig. S4B). The HK2-ASO1/MET combination triggered
apoptosis in HK1HK2þ multiple myeloma cells (Fig. 5B), and
the apoptotic effectwas enhancedbyPER(Fig. 5C; Supplementary
Fig. S4C).
Multiple myeloma tumors are found in the bone (1), an
environment proposed to protect the tumor cells from thera-
peutic agents (18). Using culture conditions, we next examined
the effect of bone marrow microenvironment interactions on
the efﬁcacy of our HK2-ASO1/MET/PER triple combination
therapy. Cocultures of luciferase (LUC) expressing HK1HK2þ
Figure 4.
HK2-ASO1/DPI/PER combination therapy effectively suppresses HK1HK2þ multiple myeloma xenograft tumor progression. A, HK2-ASO1 treatment suppresses
HK2 expression both in xenograft HK1HK2þ OPM2 and HK1þHK2þ U266 tumors. When xenograft tumors reached 200 mm3, 50 mg/kg ASO-Ctrl or HK2-ASO1
was given subcutaneously once daily for 2 weeks, prior to analyses of tumor HK1 and HK2 protein expression. H460 lung cell tumor extract was used as a
HK1þHK2þ control for the OPM2 samples. B, HK2-ASO1 treatment decreases 18F-FDG PET accumulation in xenograft OPM2 tumors. When xenograft tumors
reached 200 mm3, 50 mg/kg ASO-Ctrl or HK2-ASO1 was administered subcutaneously once daily for 10 days, prior to 18F-FDG microPET imaging. C, Quantiﬁcation
of PET signal in B. D, The HK2-ASO1/DPI/PER combination therapy effectively suppresses HK1HK2þ OPM2 xenograft tumor progression. When tumors reached
200 mm3 (day 1), xenografts were randomized into indicated groups (n ¼ 10/group). ASO-Ctrl and HK2-ASO1 treatments started on day 1 at 50 mg/kg
subcutaneously daily. DPI (2 mg/kg, daily i.p.) and PER (30 mg/kg, daily i.p.) started on day 3. Treatments were given for 5 days per week, with a 2-day break
between weeks. E, Treatment effects on OPM2 tumor HK1 and HK2 levels and PARP cleavage. H460 HK1þHK2þ lung cancer cell line lysate was used as a positive
control for HK1 expression. F, The HK2-ASO1/DPI/PER combination therapy has no detectable signiﬁcant effect on HK1þHK2þ U266 xenograft tumor progression.
N ¼ 10/group. Treatment schedule and dosages were the same as those for OPM2 xenografts.  , P < 0.05;  , P < 0.001;  , P < 0.0001. NS, not signiﬁcant.
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RPMI8226 multiple myeloma cells with human bone marrow
stromal cells (BMSC), using a 1:2 ratio of multiple myeloma
cells to BMSCs (19), did not affect the cytotoxicity of our triple
combination therapy, although the presence of BMSCs lowered
the sensitivity of RPMI8226 cells to HK2-ASO1 as a single agent
(Fig. 5D and E).
The in vivo activity of OXPHOS inhibitors can be noninvasively
monitored by 18F-FDG PET, because OXPHOS inhibition forces
Figure 5.
MET can replace DPI in the synthetically lethal combination in HK1HK2þmultiple myeloma cells. A, The combination of HK2-ASO1 and MET causes selective
synthetic lethality in HK1HK2þmultiple myeloma cells. Cells were pretreated with HK2-ASO1 (10 mmol/L) for 3 days, followed by the addition of MET (5 mmol/L)
for another 3 days. Cell viability was determined trypan blue staining. B, The combination of HK2-ASO1 and MET causes selective apoptosis in OPM2multiple
myeloma cells. Cells were pretreated with HK2-ASO1 (10 mmol/L) for 3 days, followed by the addition of MET (5 mmol/L) for another 3 days. Apoptosis (APO)
was determined by quantiﬁcation of all Annexin V-positive events. C, PER sensitized OPM2 cells to apoptosis induced by the HK2-ASO1/MET combination. Cells
were pretreated with HK2-ASO1 (5 mmol/L) for 3 days, followed by the addition of MET (2.5 mmol/L) and PER (5 mmol/L) for another 3 days. Apoptosis (APO)
was determined by quantiﬁcation of all Annexin V–positive events. D, Effects of single agents and combination treatments on RPMI8226/LUC cells with and
without BMSC coculture. In cocultures, RPMI8226/LUC cells and BMSCs were in 1:2 ratio. Cells were exposed to 10 mmol/L ASOs for an additional period of 3 days,
prior to the exposure of 15 nmol/L DPI, 2.5 mmol/L MET, and/or 5 mmol/L PER for another 3 days. RPMI8662/LUC cell proliferation was determined bymeasuring
luminescence intensity. E, Representative images of cocultures of RPMI8226/LUC and BMSCs with indicated treatments shown in D. F, The combinations of HK2-
ASO1/MET/PER and HK2-ASO1/DPI/PER show no demonstrably signiﬁcant differences in suppressing xenograft OPM2 tumor progression. When tumors
reached 200mm3 (day 1), xenografts were randomized into indicated groups (n¼ 10/group). HK2-ASO1 treatment was started on day 1 at 50mg/kg s.c. daily.
DPI (2 mg/kg, daily i.p.), MET (250mg/kg, daily i.p.), and PER (30mg/kg, daily i.p.) were started on day 3. Treatments were given for 5 days per week, with a
2-day break between weeks. NS, not signiﬁcant. G, Disease progression in the HK1HK2þ RPMI8226/LUC disseminated xenograft model was monitored by BLI.
BLI measurement in photons per second per cm2 per steradian (p/s/cm2/sr) was translated to color to indicate disease activity in the mice by the scales shown at
far right. H,Quantiﬁcation of whole mouse BLI photons in G.  , P < 0.001;  , P < 0.0001.
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cells to upregulate glycolytic activity to compensate loss in energy
production, resulting in an increase in 18F-FDG PET signal. MET
andDPI treatments comparably increased 18F-FDG accumulation
inHK1HK2þOPM2multiplemyeloma tumors (Supplementary
Fig. S4D).
Although MET alone did not signiﬁcantly affect OPM2 tumor
progression (Fig. 5F), the HK2-ASO1/MET/PER combination was
comparable to the HK2-ASO1/DPI/PER combination both in
suppression of subcutaneous HK1HK2þ tumor progression
(Fig. 5F) and in PARP cleavage induction (Supplementary Fig.
S4E). These results support replacing DPI with MET to translate
this combination therapy into a precision medicine therapy
alternative to treat patients with HK1HK2þ multiple myeloma.
Multiplemyeloma is a systemic hematopoietic disease. To exam-
ine the efﬁcacy of the triple therapy on systemic multiple myeloma
progression, we used a previously validated systemic multiple
myeloma model with human HK1HK2þ RPMI8226/LUC
cells (19). Following intravenous injection of multiple myeloma
cells, cohorts of mice were treated either with ASO-Ctrl or with the
HK2-ASO1/MET/PER combination therapy, and disease progres-
sion was monitored by BLI at the times indicated in Fig. 5G. As
observed for subcutaneous human HK1HK2þ OPM2 tumors
(Fig. 5F), systemic HK1HK2þ RPMI8226/LUC tumor progression
wasdramatically reducedby the triple combination (Fig. 5GandH).
HK2-ASO1/DPI/PER and HK2-ASO1/MET/PER combination
therapies have similar impacts on HK1HK2þ multiple
myeloma cell metabolism
By targeting OXPHOS, both DPI and MET increased glycolysis
in OPM2 cells, whereas HK2-ASO1 blocked HK2-driven glycol-
ysis (Fig. 6A). Consistent with these observations, co-inhibition
of HK2-driven glycolysis and OXPHOS reduced cellular
Figure 6.
Impact of HK2-ASO1, DPI, MET, and PER on HK1HK2þOPM2 cell metabolism. Effects of HK2-ASO1, DPI, MET, and PER, alone and in combination for 24 hours, on
OPM2 glucose consumption and lactate production (A), and cellular ATP/(AMPþADP) ratios (B). C,OPM2 cell viability after 24-hour treatments with HK2-ASO1,
DPI, MET, and PER, alone and in combination, determined by trypan blue staining. No signiﬁcant differences could be detected between the vehicle control and
any of the experimental treatment groups. D, Effects of HK2-ASO1, DPI, MET, and PER, alone and in combination for 24 hours, on the levels of 129 important
metabolites in OPM2 cells. E, Effects of 24-hour treatments with HK2-ASO1/DPI/PER and HK2-ASO1/MET/PER on relative changes in cellular pool sizes of amino
acids, TCA cycle metabolites, fatty acid intermediates, purines and pyrimidines in OPM2 cells. F, Effects of 24-hour treatments with HK2-ASO1/DPI/PER and
HK2-ASO1/MET/PER on relative changes in 13C portions of amino acids, TCA cycle metabolites, purines, and pyrimidines in OPM2 cells.
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ATP/(AMPþADP) ratios more than single pathway inhibition.
Although FAO inhibition alone byPERhas no signiﬁcant effect on
the ATP/(AMPþADP) ratio, FAO inhibition reduced the ATP/
(AMPþADP) ratios in HK1HK2þ OPM2 cells exposed both to
HK2-ASO1þDPI and to HK2-ASO1þMET (Fig. 6B). These met-
abolic changes occurred prior to cell death (Fig. 6C).
Global metabolic proﬁling demonstrated thatMET andDPI, as
single agents, exert essentially identical effects on cell metabolism
(Fig. 6D). The combinations of HK2-ASO1þDPIþPER and
HK2-ASO1þMETþPER share similar patterns ofmetabolic altera-
tions, distinct from metabolic alterations elicited by the single
agents (Fig. 6D). In particular, the triple-combinations (HK2-
ASO1þDPIþPER and HK2-ASO1þMETþPER) substantially
decreased the intracellular pool sizes of many amino acids, nearly
all metabolites in the TCA cycle, some fatty acid intermediates,
and all metabolites in purine and pyrimidine biosynthesis
(Fig. 6E; Supplementary Fig. S5; Supplementary Table S1). The
triple-combination therapies substantially altered the global
metabolism of HK1HK2þ multiple myeloma cells, likely con-
tributing to the synthetic lethality.
Using [U-13C]-glucose as a carbon source to label metabolites
de novo synthesized, we further observed that the 13C-labeled
portions of many amino acids, metabolites in the TCA cycle and
nucleotide biosynthesiswere substantially decreased by the triple-
combinations (Fig. 6F; Supplementary Fig. S6). Taken together,
our results indicate that the triple-combinations HK2-ASO1/
MET/PER and HK2-ASO1/DPI/PER induce global metabolic
alterations similar to one another, and distinct from those elicited
by single agents; the triple-combinations reduce both the pool
sizes of many key metabolites and their de novo, glucose-
dependent biosynthesis.
HK2-ASO/DPI/PER and HK2-ASO/MET/PER combinations are
tolerated by normal tissues
Although the triple-combinations using HK2-ASO1 show efﬁ-
cacy in suppressing humanHK1HK2þmultiplemyeloma tumor
progression in xenograft models (Fig. 5F–H), it remained unclear
whether mice can tolerate the triple-combination with HK2
inhibition in normal tissues; the mRNAs for mouse and human
HK2 differ in sequence and are, consequently, likely to differ in
inhibition by ASOs directed against HK2 from the alternative
species. To address this question, two ASOs, mHK2-ASO1 and
mHK2-ASO2 (Supplementary Fig. S7A) were developed to be
tested inHK2-ASO/DPI/PER andHK2-ASO/MET/PER triple-com-
binations in mice bearing mouse HK1HK2þ multiple myelo-
mas. As anticipated, HK2-ASO1 targets human HK2 but not
mouse HK2 (Supplementary Fig. S7B).
mHK2-ASO1 and mHK2-ASO2 suppressed mouse HK2
expression in mouse multiple myeloma P3  63Ag (P3)
cells (20) without affecting HK1 expression (Supplementary
Fig. S7C). To model human HK1HK2þ multiple myelomas,
isogenic HK1HK2þ mouse P3 cells were generated using
CRISPR-Cas9 deletion (Supplementary Fig. S7D). Both
mHK2-ASO1 and mHK2-ASO2 suppressed HK2 expression to
equivalent degrees in the parental P3 cells and in the P3 HK1KO
cells (Fig. 7A; Supplementary Fig. S7C). Although ASO-mediated
HK2 knockdown did not affect proliferation of parental
HK1þHK2þ P3 cells in culture, both mHK2-ASO1 and mHK2-
ASO2 inhibited proliferation of the isogenic HK1HK2þ
P3/HK1KO cells (Supplementary Fig. S7E). mHK2-ASO1/DPI/
PER and mHK2-ASO1/MET/PER triple-combinations induced
similar synthetic lethality responses in cultured HK1HK2þ P3
HK1KO cells (Fig. 7B).
In mice bearing subcutaneous isogenic HK1HK2þ and
HK1þHK2þ P3 tumors, mHK2-ASO1 and mHK2-ASO2 both
reduced HK2 levels in tumors and to a lesser extent in the heart
(Supplementary Fig. S7F). In contrast, neither mHK2-ASO1 nor
mHK2-ASO2 affected HK2 expression in skeletal muscle (Sup-
plementary Fig. S7F). As expected, neither mHK2-ASO1 nor
mHK2-ASO2 affected HK1 expression (Supplementary Fig.
S7F). 18F-FDG PET scans demonstrated signiﬁcantly decreased
18F-FDG accumulation in subcutaneous HK1HK2þ P3 tumors
after mHK2-ASO1, mHK2-ASO1/MET/PER, or mHK2-ASO1/
DPI/PER treatments (Fig. 7C). mHK2-ASO1 alone signiﬁcantly
reduced HK1HK2þ P3 tumor progression (Fig. 7D). Moreover,
mHK2-ASO1/MET/PER andmHK2-ASO1/DPI/PER substantially
and equivalently decreased subcutaneous HK1HK2þ P3 tumor
progression compared with mHK2-ASO1 alone (Fig. 7D). At the
experiment endpoint, tumors were collected (Supplementary Fig.
S7G), weighed (Supplementary Fig. S7H), and analyzed for HK2
expression (Supplementary Fig. S7I). Both mHK2-ASO1/MET/
PER and mHK2-ASO1/DPI/PER triple-combinations were toler-
ated by themice as indicated by body weight (Fig. 7E). These data
suggest that the HK2 ASOþMETþPER combination is likely to be
tolerated for human HK1HK2þ multiple myeloma therapy.
We also established a disseminated mouse multiple myeloma
model, using intravenous injected P3HK1HK2þ cells expressing
both LUC (for BLI imaging) and mCherry (for ﬂuorescent quan-
tiﬁcation of multiple myeloma cells in bone marrow extracts).
Bone marrow extraction on day 18 post-injection identiﬁed 27.2
 4.2% of the cells as mCherry-labeled multiple myeloma cells
(Supplementary Fig. S7J). The mHK2-ASO1/MET/PER combina-
tion signiﬁcantly suppressed the progression of this highly aggres-
sive disseminated mouse multiple myeloma model, as deter-
mined by BLI (Fig. 7F and G). The experiment was terminated
following euthanizationof the last controlmouse; all treatedmice
were alive and appeared healthy at the end of the experiment
(Fig. 7H). These data demonstrate, in the mouse systemic model,
that the triple-combination shows efﬁcacy in suppressing
HK1HK2þ multiple myeloma tumor progression and is toler-
ated by normal tissues.
Discussion
It is only relatively recently that HK2 expression has been
recognized as a common feature of many cancers (7, 8, 10,
21). Because HK2 is not expressed in most normal tissues,
targeting HK2 has become a popular goal as an approach to
cancer management. In the absence of systemically effective
selective HK2 inhibitors, several laboratories, using HK2-targeted
shRNAs, reported success in retarding, reducing, or eliminating
HK1þHK2þ xenograft tumor progression (7, 8, 10, 21). However,
when this question was reexamined, both with alternative HK2
shRNAs and with isogenic HK1 HK2þ and HK1þHK2þ cancer
cell line pairs created by CRISPR Cas9 deletion, it became clear
that HK1 and HK2 can compensate each other; either is sufﬁcient
to support cancer cell proliferation in culture and for xenograft
tumor progression in vivo (11). Consistent with these observa-
tions, neither HK2 nor HK1 were identiﬁed as essential genes for
cell proliferation in anunbiased systematic CRISPRCas9 screen of
HK1þHK2þ cancer cell lines (22). In contrast, however, HK2
shRNA expression was cytostatic for HK1HK2þ cancer cells, and
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reduced, but did not eliminate, HK1HK2þ xenograft tumor
progression in vivo (12).
In examining the HK isoform expression of human cancer cell
lines in the CCLE collection it became clear that liver cancers and
multiple myelomas have the greatest percentages of HK1HK2þ
cell lines. Because examination of the TCGA data base revealed
that primary liver cancer specimens are enriched in HK1HK2þ
samples, we turned ﬁrst to these tumors to develop an effective
experimental therapy for HK1HK2þ tumors that incorporates
elimination of HK2 activity. We demonstrated that combined
HK2shRNA knockdown and mitochondrial complex I inhibition
achieves synthetic lethality in HK1HK2þ liver cancer cells, and
Figure 7.
In vitro and in vivo effects of mouse HK2 ASOs as single agents and in combination with DPI, MET, and PER. A,mHK2-ASO1 suppresses HK2 expression in
HK1HK2þ P3 cells. B, The combinations of mHK2-ASO1/DPI/PER andmHK2-ASO1/MET/PER induce apoptosis in HK1HK2þ P3 cells. Cells were pretreated with
mHK2-ASO1 (0.5 mmol/L) for 3 days, followed by the addition of MET (2 mmol/L), DPI (25 nmol/L), and PER (3 mmol/L) for another 3 days. Apoptosis (APO) was
determined by quantiﬁcation of the Annexin V-positive population. C, Eight-day treatments with mHK2-ASO1, mHK2-ASO1/MET/PER, and mHK2-ASO1/DPI/PER
signiﬁcantly reduced 18F-FDG PET signal in mouse HK1HK2þ P3 tumors. Left, PET scan images are shown. Right, quantiﬁcation of PET signal intensity from
tumor ROI values.D, Effects of mHK2-ASO1, mHK2-ASO1/MET/PER, and mHK2-ASO1/DPI/PER on HK1HK2þ P3 tumor progression. When tumors reached 200
mm3 (day 1), mice were randomized into indicated groups (n¼ 11/group). mHK2-ASO1 treatment started on day 1 at 50 mg/kg s.c. daily. DPI (2 mg/kg, daily i.p.),
MET (250 mg/kg, daily i.p.), and PER (30mg/kg, daily i.p.) started on day 3. Treatments were given for 5 days per week, with a 2-day break between weeks. NS,
not signiﬁcant. E, Body weight of the four indicated groups during treatments. F, Disease progression in the P3/HK1/mCherry-LUC disseminated model was
monitored by BLI. BLI measurement in photons per second per cm2 per steradian (p/s/cm2/sr) was translated to color to indicate disease activity in the mice
by the scales shown at far right. G,Quantiﬁcation of whole mouse BLI photons in F. H, Kaplan–Meier survival curves of mice in F.  , P < 0.05;  , P < 0.01;
 , P < 0.001;  , P < 0.0001.
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determined that FAO inhibition by PER, in combination with
HK2shRNA knockdown and OXPHOS inhibition, prevented liver
HK1HK2þ tumor xenograft progression (12).
In this study our goals were to determine whether HK1HK2þ
multiple myelomas were also susceptible to synthetic lethality
mediated by inhibition of HK2 expression, OXPHOS and FAO,
and to identify inhibitory agents for each component that are
more appropriate for clinical application. Despite substantial
attempts (17), no systemically efﬁcacious targeted HK2 inhibitor
has been reported. To move the HK2shRNA/DPI/PER combination
therapy described previously (12) toward treatment forHK1HK2þ
multiple myelomas, we replaced HK2 shRNA with HK2-ASO1 to
reduce HK2 expression. To our knowledge, HK2-ASO1 is the ﬁrst
pharmaceutical agent with a systemic in vivo ability to reduce HK2
activity, with little or no effect on HK1 activity, in tumors.
A signiﬁcant advantage of ASOs relative to traditional small
molecule-based drugs is their exquisite target speciﬁcity. Metabolic
reprogramming in cancer frequently results frommetabolic enzyme
isoformswitches (12, 23–25). ThemRNAsequences of these cancer-
speciﬁc isoformscanbeexploited to target cancer cells,withminimal
effects on normal tissues that express different enzyme isoforms.
Because of the extensive similarities in protein structures and sub-
strate binding sites between these enzyme isoforms, targeting the
cancer-speciﬁc isoforms by ASOs to exploit isoform-speciﬁc differ-
ences inmRNAsequencesprovides apromising therapeutic strategy.
Again, to use more clinically relevant agents for the HK2i/
OXPHOSi/FAOi combination therapy, we replaced the potent
mitochondrial complex I inhibitor DPI (12) with an FDA-
approved inhibitor, MET. MET can replace DPI in proliferation
and viability studies, global metabolomics analyses, 18F-FDG/
microPET imaging, and tumor xenograft progression. PER is in
clinical use as an antianginal drug in Asia and Australia, and in
phase II/III clinical trials in the United States.
Tumor cell expression of shRNAs targeting human HK2 in
xenograft models (7, 8, 10, 21) cannot properly evaluate adverse
effects of HK2 inhibition in normal tissues; because of differences
in human and mouse HK2 mRNA sequences, ASOs that target
human HK2 have no effect on mouse HK2 expression (Supple-
mentary Fig. S7B). However, using a mouse multiple myeloma
tumor/host model, the mouse HK2-ASOs/MET/PER therapeutic
combination exhibits both potency and safety, suggesting that
HK2-ASO1/MET/PER could be tolerated by normal tissues in
patients. Consequently, an HK2-ASO/MET/PER combination
could be a promising translational precision medicine therapy
forHK1HK2þmultiplemyelomas. Additional studies need to be
done to further identify HK2-ASOs suitable for clinical investiga-
tion. In addition, the clinical potential of our observations can be
further validated by future experiments that use primary patient-
derived HK1HK2þ multiple myeloma cells and patient-derived
xenograft models of HK1HK2þ multiple myelomas.
Stratiﬁcation of patients with multiple myeloma to identify
those individuals whose tumors are HK1HK2þ would be
required for the clinical success of this precisionmedicine therapy.
Due to HK1 expression in most normal tissues, and consequent
contamination with noncancer HK1-expressing cells in tumor
biopsies, single-cell analyses with multiple myeloma marker
staining (e.g., CD138, BCMA) are likely to be required for patient
stratiﬁcation. In addition tomultiplemyeloma, other cancers also
have HK1HK2þ subsets (11). These HK1HK2þ cancers are also
susceptible to HK2 inhibition, regardless of their tissues of ori-
gin (11). Therefore, in combination with patient stratiﬁcation
strategies, an HK2-ASO/MET/PER combination has potential as a
precision medicine therapy to treat HK1HK2þ tumors, regard-
less of their tissue of origin.
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